F8B30

F8B30 is a first-in-class monoclonal antibody designed as an immune checkpoint inhibitor targeting the Killer cell immunoglobulin-like receptor 2DL5 (KIR2DL5). Developed by researchers at the Albert Einstein College of Medicine, this biologic therapeutic binds with high affinity (KD = 0.72 nM) to KIR2DL5, an inhibitory receptor expressed on natural killer (NK) cells. By blocking the interaction between KIR2DL5 and its ligand, the poliovirus receptor (PVR/CD155) found on tumor cells, F8B30 prevents the suppression of NK cell-mediated cytotoxicity. This mechanism allows NK cells to effectively recognize and eliminate cancer cells. Preclinical studies in humanized mouse models have demonstrated that the antibody can significantly reduce tumor growth and improve survival across multiple cancer types. The technology is currently in preclinical development and is the subject of patent applications by the developing institution.

Other names

anti-KIR2DL5 monoclonal antibodyanti-KIR-2DL5 monoclonal antibodyanti-KIR 2DL5 monoclonal antibodyanti-KIR2DL5 mAbanti-KIR-2DL5 mAbanti-KIR 2DL5 mAb